What is the maximum daily dose of bupropion?

And why that is the wrong first question — the ceiling is set by the product and the indication, and a daily total can be perfectly correct while two other rules are broken.

How many rules are there, and which one gets missed?

Three. The daily total is the one everyone checks; the single-dose limit and the minimum interval are the two that a double-up or a consolidated schedule quietly breaks.

Every bupropion product carries all three, and each has its own values for each. The reason this matters more for bupropion than for most antidepressants is mechanistic: seizure risk with this drug tracks peak concentration, not just total exposure. A patient who takes their whole day's dose in one administration has the same daily total on the chart and a substantially different peak.

That is why the two unchecked rules are the clinically interesting ones. The three commonest ways they break are worth naming, because none of them looks like an error at the time:

• Two strengths dispensed together, and the patient takes both at once rather than at separate times.
• A missed morning dose taken alongside the evening one, which is what most patients do by default unless told otherwise.
• An immediate-release schedule consolidated from three or four administrations into fewer, usually to make it easier to remember or to fit around work.

All three produce a correct daily total. None of them is visible on a medication list.

So what is the maximum daily dose?

It depends on the product and on the indication. There are eight answers in US labelling, not one.

The table below is the whole argument. Read down the first column, find the product actually in front of you, and read across. The point is not to memorise it — it is that memorising a single number is what produces the error.

Two things in that table are worth pausing on. The first is the third row: the same salt, in the same formulation, carries a lower ceiling when it is prescribed for smoking cessation than when it is prescribed for depression. Formulation alone does not determine the maximum. The second is the sixth row, which is the one most likely to be misread on a reconciliation list.

Why does the extended-release ceiling have two numbers?

Because it genuinely differs between marketed products, and because the standard label's own seizure section names two figures a few lines apart.

Current standard extended-release labels — brand and generic alike — open the seizure subsection with an instruction that the dose should not exceed 300 mg once daily. That is not the only figure the label gives, and it is not the most prominent one.

The Highlights section at the top of the label, which is the part most prescribers actually consult, states that the risk of seizure can be reduced by limiting the daily dose to 450 mg. The incidence paragraph inside the seizure subsection says the same, a few lines below the 300 mg instruction. In Highlights, 300 mg appears only as the usual target dose — not as a ceiling at all.

So one label names two different ceilings in two different places, and the more prominent placement carries the higher number. Whether the opening imperative or the Highlights figure governs is not something this post can settle, and it is not something a table cell can carry. It is the reason the row above says the ceiling is contested rather than picking one.

Meanwhile a single-strength 450 mg extended-release product exists, is dosed at exactly 450 mg once daily because that is its only available strength, and is labelled not to be used to start treatment — patients are titrated on another bupropion product first. Its own seizure subsection, consistent with having one strength, states no numeric ceiling at all.

So a clinician who carries “extended release goes to 450” will over-dose one product, and a clinician who carries “extended release caps at 300” will under-treat on another. The number cannot be recalled. It has to be read off the product in hand.

What about the bupropion that is not called bupropion?

Two combination products deliver substantial bupropion, and neither is filed mentally as a bupropion prescription by the clinician writing it.

A naltrexone–bupropion combination licensed for weight management delivers 360 mg of bupropion hydrochloride a day at maintenance, as two tablets twice daily, each containing 90 mg. A dextromethorphan–bupropion combination licensed for depression delivers 210 mg a day, as one tablet twice daily at least eight hours apart.

The clinical consequence is a stacking problem rather than a dosing problem. A patient started on the weight-management combination by one clinician and given bupropion for depression by another is receiving both, and neither prescriber sees a bupropion duplication on their own list. Bupropion labelling is explicit that other bupropion-containing products are among the medications that lower the seizure threshold. Asking “are you on anything else with bupropion in it?” is a different question from reading the medication list, and it is the one that finds this.

Does any of this actually change seizure risk?

Yes, and unusually for an adverse effect, the labels quantify it.

Sustained release runs at approximately 0.1% — one in a thousand — at doses up to 300 mg/day, and approximately 0.4%, four in a thousand, at its 400 mg/day ceiling. That is a fourfold rise inside a single formulation and entirely within licence. Immediate release sits at approximately 0.4% at doses up to 450 mg/day, and the estimated incidence rises almost tenfold between 450 and 600 mg/day.

Those figures are worth holding precisely because they are unusual. Most of what we counsel patients about carries no number at all. Here the dose–risk relationship is on the label, which means the difference between a correct and an incorrect ceiling is not theoretical.

What would I actually do differently on Monday?

Three things, none of which takes longer than a few seconds.

• When bupropion appears on a list, establish the formulation and the indication before you consider the number. “Bupropion 150 mg” is not enough information to know whether it is correct.
• Tell the patient explicitly what to do about a missed dose. The default behaviour — take it with the next one — is the single most common way the single-dose rule gets broken, and it is prevented by one sentence at the first visit.
• Ask directly about other bupropion-containing products, including anything prescribed for weight. The medication list will not answer this for you.